
Dave Sekera
Chief U.S. Market Strategist at Morningstar. Co-host of The Morning Filter podcast.
Top 10 podcasts with Dave Sekera
Ranked by the Snipd community

42 snips
Feb 10, 2025 • 44min
3 More Stocks to Buy Before They Rebound
In a fascinating discussion, Dave Sekera, the Chief U.S. markets strategist at Morningstar, shares his insights on current market volatility driven by earnings and geopolitical factors. He unpacks the implications of tariffs on various industries while focusing on analyzing inflation trends through upcoming economic reports. Sekera also evaluates recent earnings from Gilead and Kraft Heinz, dives into stock performance for tech giants like Alphabet and Amazon, and highlights strong growth potential in the AI sector.

32 snips
Feb 24, 2025 • 35min
3 Stocks to Buy While the Market Hits New Highs
Dave Sekera, Morningstar's Chief U.S. markets strategist, dives into economic trends and stock analysis. He discusses the significance of GDP and inflation changes, offering a cautionary outlook on the market. The conversation shifts to NVIDIA, analyzing expectations ahead of its earnings report and its performance in AI workloads. Sekera also evaluates Walmart, Gilead Sciences, and Hasbro's recent financial results, revealing investment potentials amidst evolving consumer habits and market dynamics.

20 snips
Mar 3, 2025 • 39min
3 Stocks to Sell and 3 Stocks to Buy in March
Join Dave Sekera, Chief U.S. Markets Strategist at Morningstar, as he shares insights on the current stock landscape. He dissects economic indicators, including key payroll data, and the performance of AI stocks like NVIDIA. Dave also discusses stocks to sell—like Eli Lilly and Wingstop due to valuation concerns—and highlights promising picks such as W.K. Kellogg. With a focus on value stocks and high dividend yields, his expert analysis equips listeners with actionable investment strategies amidst a complex market.

19 snips
Jan 14, 2025 • 50min
Dave Sekera: A Market Outlook for 2025 and Beyond
Dave Sekera, Chief US Market Strategist at Morningstar Research Services, shares his insights into the economic outlook for 2025. He discusses the overvaluation of growth stocks, emphasizing the appeal of value stocks. Sekera highlights the undervalued healthcare sector and potential opportunities arising from falling inflation and interest rates. Additionally, he touches on the importance of strong economic moats for competitive advantage and the need for a strategic shift in investment approaches in the evolving market landscape.

16 snips
Dec 22, 2025 • 55min
4 Cheap Stock Picks We Still Like for 2026
Dave Sekera, Morningstar's Chief U.S. Market Strategist, shares insightful stock analysis and investment philosophy. He reflects on the importance of reviewing past stock picks and the lessons learned from wins and losses. Dave discusses several companies, including Baxter's challenges, Alphabet’s strong fundamentals due to AI innovations, and AMD’s strategic partnerships. He wraps up by highlighting four undervalued stocks for 2026: Biogen, Microsoft, LPL Financial, and Devon Energy, showcasing their potential for future gains.

12 snips
Mar 10, 2025 • 31min
4 Stocks to Buy During Tariff Uncertainty
In this discussion, Dave Sekera, Morningstar's Chief U.S. markets strategist, dives into the impact of tariff uncertainty on the stock market. He highlights intriguing stock picks like Dollar General and Adobe amidst economic fluctuations. Sekera emphasizes the shift toward value stocks, spotlighting healthcare and energy sectors as ripe for investment. He also identifies Clorox as an undervalued gem in consumer defense, showcasing its strong brand and dividend yield. Tune in for insights on navigating the evolving market landscape!

10 snips
Sep 5, 2025 • 18min
Investing in AI? Here Are 6 Undervalued Stocks for Buy-and-Hold Investors
Dave Sekera, Chief US Market Strategist at Morningstar Research Services, dives into the complexities of investing in AI. He discusses whether the AI hype marks a genuine boom or a speculative bubble. The conversation shifts to Nvidia's pivotal role amidst US-China tensions and its potential market opportunities. Sekera also highlights specific undervalued stocks, like ASML and Microsoft, as promising investments. This lively exchange is packed with insights on navigating the evolving landscape of AI investments.

Jun 16, 2025 • 41min
The Morning Filter: 5 Rallying Stocks to Buy in June While They’re Still Undervalued
In this episode, Dave Sekera, Chief U.S. Market Strategist at Morningstar, and Damien Conover, Director of Equity Research, dive into intriguing stock market dynamics. They assess the Federal Reserve's potential interest rate cuts and review recent earnings, particularly from Adobe. Damien highlights sectors vulnerable to tariffs and suggests stock strategies to navigate market uncertainties. Listeners also gain insights on how geopolitical tensions may impact U.S. stocks, alongside recommendations for undervalued investments to watch.

Mar 24, 2025 • 33min
3 Stocks to Buy of Companies with Top-Rated Management
Dave Sekera, Chief U.S. Markets Strategist at Morningstar, shares his insights on stock investing and market trends. He discusses strategies for small cap stocks and their implications on portfolio management. Sekera analyzes the challenges faced by Western Union and Comcast, highlighting their market positions and financial strengths. He also evaluates Illinois Toolworks, emphasizing its economic moat, and sheds light on Amazon's top-rated management and strong acquisitions, making compelling cases for these stocks as solid investment opportunities.

Feb 3, 2025 • 36min
3 Stocks to Buy Before They Bounce Back
In this engaging discussion, Dave Sekera, Morningstar's Chief U.S. markets strategist, shares his insights on the economy and investment strategies. He explores the impact of new tariffs on trade and stock prices. The conversation delves into upcoming earnings from major companies like Alphabet and Amazon, and how inflation is shaping market dynamics. Sekera gives a spotlight to undervalued stocks, analyzing Microsoft and Lockheed Martin as strong picks. He also examines the booming obesity drug sector and reviews the implications of AI developments on tech stocks.


